Stada Gears Up For Higher-Strength Adalimumab As Alvotech Clears Up Legal Overhang

Iceandic Firm Has Settled European IP Disputes With Originator AbbVie

 
• By Chloe Kent

Alvotech and its strategic partner Stada are preparing to launch their higher-strength adalimumab candidate AVT02 in Europe after settling intellectual property disputes with originator AbbVie.

Two thumbs up
Hukyndra was approved by the European Commission in November last year. • Source: Alamy (Alamy Stock Photo)

More from Biosimilars

More from Products